UroGenesys, Protein Pathways Form Alliance for Cancer Genomics and Proteomics

Mar 09, 2000

Premium

S

ANTA MONICA, Calif.--UroGenesys and Protein Pathways have formed an alliance to apply Protein Pathways’ bioinformatics technologies to UroGenesys’ database of cancer-associated antigens. The companies expect the combination of their genomics and proteomics expertise to uncover functional information that will guide therapeutic development of UroGenesys’ antigens, as well as identify new product candidates for cancer therapy. Financial terms of the collaboration were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Main menu